Latest news with #stemcells
Yahoo
27-05-2025
- Business
- Yahoo
Induced Pluripotent Stem Cell (iPSC) Industry Report 2025-2030: iPSCs Set to Redefine Clinical and Research Paradigms, iPSC Technology Drives Innovation in Regenerative Therapy
Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" has been added to offering. The market for iPSC-derived products continues expanding with involvement from companies like Lonza, BD Biosciences, and Thermo Fisher Scientific, among others. Over 90 companies actively engage in this market, offering diverse products and technologies for research and therapeutic applications. Since discovering iPSCs 18 years ago, remarkable advancements have occurred. It saw its first human application in 2013, and now at least 155 clinical trials use iPSCs globally. iPSCs are being tested for various conditions, including Parkinson's disease, cancer immunotherapies with iNK cells, age-related macular degeneration, and Type 1 diabetes. This diversity underscores iPSCs' transformative potential in treating numerous diseases. Commercially, companies harness iPSC products for drug development, disease modeling, and toxicology testing. Notable players include FUJIFILM Cellular Dynamics International (FCDI), a leader in iPSC-derived human cell production, and ReproCELL, pioneering iPSC product commercialization. Europe also hosts major competitors like Evotec and Ncardia, specializing in drug screening and cardiac applications, respectively. The potential of iPSCs to redefine medicine and biotechnology is substantial. As iPSC applications evolve in disease modeling, drug discovery, and cell therapies, they drive innovation within healthcare and research, paving the way for transformative advancements. This comprehensive report outlines key players, strategic partnerships, and innovations propelling the sector. It details advancements in iPSC research, manufacturing, and clinical developments, alongside an analysis of the funding landscape. Projected market growth rates through 2030, categorized by application, technology, cell types, and geography, offer insights into iPSC industry's future. Current Commercialization Methods of iPSCs: Cellular Therapy: iPSCs are being explored for cell therapy applications to repair injuries or cure diseases by substituting damaged cells. Disease Modeling: Patient-specific iPSCs are differentiated into disease-specific cells, creating functional models for research. Drug Development: iPSCs deliver physiologically relevant cells for drug discovery, enhancing the efficacy of compound identification, target validation, and screening processes. Personalized Medicine: Integration with genome-editing technologies facilitates customized treatments by modifying iPSCs at the genetic level. Toxicology Testing: Screening iPSCs or derivatives to evaluate compound safety and efficacy reduces dependence on animal testing. Tissue Engineering: Culturing iPSCs on biocompatible scaffolds supports engineered tissue development for transplantation. Organoid Production: Self-organizing iPSCs form 3D organoids, facilitating organ study, disease modeling, and drug testing. Gene Editing: Techniques like CRISPR enable iPSC modifications for mutation correction, facilitating functional cell development for treatments. Research Tools: Extensive research applications include studying cellular processes and testing experimental therapies with iPSCs. Stem Cell Banking: iPSC repositories offer diverse cell types for research, allowing investigations into conditions using samples from various donors. Cultured Meat Production: iPSCs serve as cellular bases for lab-grown meat production, promoting sustainable alternatives. 3D Bioprinting: Differentiated iPSCs are used in bioinks for creating complex tissue structures via 3D bioprinting. Key Topics Covered: 1. REPORT OVERVIEW1.1 Statement of the Report1.2 Executive Summary 2. INTRODUCTION 3. CURRENT STATUS OF IPSC INDUSTRY3.1 Progress made in Autologous Cell Therapy using iPSCs3.2 Allogeneic iPSC-based Cell Therapies3.3 Share of iPSC-based Research within the Overall Stem Cell Industry3.4 Major Focus Areas of iPSC Companies3.5 Commercially Available iPSC-derived Cell Types3.6 Relative use of iPSC-derived Cell Types in Toxicology Testing Assays3.7 iPSC-derived Cell Types used in Clinical Trials3.8 Currently Available iPSC Technologies 4. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)4.1 First iPSC Generation from Mouse Fibroblasts, 20064.2 First Human iPSC Generation, 20074.3 Creation of CiRA, 20104.4 First High-Throughput Screening using iPSCs, 20124.5 First iPSC Clinical Trial Approved in Japan, 20134.6 First iPSC-RPE Cell Sheet Transplantation for AMD, 20144.7 EBiSC Founded, 20144.8 First Clinical Trial using Allogeneic iPSCs for AMD, 20174.9 Clinical Trial for Parkinson's Disease using Allogeneic iPSCs, 20184.10 Commercial iPSC Plant SMaRT Established, 20184.11 First iPSC Therapy Center in Japan, 20194.12 First U.S.-based NIH-Sponsored Clinical Trial using iPSCs, 20194.13 Cynata Therapeutics' World's Largest Phase III Clinical Trial, 20204.14 Tools and Know-how to Manufacture iPSCs in Clinical Trials, 20214.15 Production of in-house iPSCs using Peripheral Blood Cells, 2022 5. RESEARCH PUBLICATIONS ON IPSCS5.1 Rapid Growth in iPSC Publications 6. IPSC: PATENT LANDSCAPE ANALYSIS6.1 iPSC Patent Applications by Jurisdiction6.2 iPSC Patent Applicants6.3 Inventors of iPSC Patents6.4 iPSC Patent Owners6.5 Legal Status of iPSC Patents 7. IPSC: CLINICAL TRIAL LANDSCAPE7.1 Number of iPSC Clinical Trials7.1 Recruitment Status of iPSC Clinical Trials7.3 iPSC Clinical Trials Stydy Designs7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials7.5 iPSC-based Trials by Phase of Study7.6 iPSC Clinical Trials by Funder Type7.7 Geographic Distribution of iPSC-based Clinical Trials7.8 Promising iPSC Product Candidates7.9 Companies having Preclinical iPSC Assets 8. M&A, COLLABORATIONS & FUNDING ACTIVITIES IN IPSC SECTOR8.1 Mergers and Acquisitions (M&A) Sector8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector8.3 Venture Capital Funding in iPSC Sector 9. GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)9.1 OSKM Cocktail9.2 Pluripotency-Associated Transcription Factors and their Functions9.3 Delivery of Reprogramming Factors9.4 Genome Editing Technologies in iPSC Generation9.5 Available iPSC Lines and their applications 10. HUMAN IPSC BANKING10.1 Major Biobanks Storing iPSCs & iPSC Lines10.2 Cell Sources for iPSC Banks10.3 Reprogramming Methods in iPSC Banks10.4 Ownership and Investments made in iPSC Banks 11. BIOMEDICAL APPLICATIONS OF IPSCs11.1 iPSCs in Basic Research11.2 Applications of iPSCs in Drug Discovery11.3 Applications of iPSCs in Toxicology Studies11.4 Applications of iPSCs in Disease Modeling11.5 Applications of iPSCs in Cell-Based Therapies11.6 Other Novel Applications of iPSCs 12. MARKET ANALYSIS12.1 Global Market for iPSCs by Geography12.2 Global Market for iPSCs by Technology12.3 Global Market for iPSCs by Biomedical Application12.4 Global Market for iPSCs by Derived Cell Type12.5 Market Drivers12.6 Market Restraints 13. COMPANY PROFILES For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
23-05-2025
- Health
- Associated Press
R3 Stem Cell Publishes Podcast Called Stem Cell Genius to Educate Consumers on Regenerative Medicine
The world's largest provider of regenerative therapies, R3 Stem Cell, has launched a new podcast called Stem Cell Genius. 'With R3's Podcast Stem Cell Genius, we will provide accurate information to FAQ's in layman's terms so people understand what these wonderful stem cell and exosome therapies can or can't do!'— David Greene, MD, PhD, MBA SCOTTSDALE, AZ, UNITED STATES, May 23, 2025 / / -- The world's largest provider of regenerative therapies, R3 Stem Cell, has launched a new podcast called Stem Cell Genius. The podcast will touch on regenerative medicine subjects that will educate consumers on frequently asked questions and provide accurate information to delineate fact from fiction in the industry. The topics will be generated from the vast majority of frequently asked questions received on a daily basis. For instance, in the first episode R3 Stem Cell CEO David Greene, MD, PhD, MBA, explains the basics of what stem cells and exosomes are. In the second episode, Dr. Greene clarifies the differences between stem cells used in the USA versus internationally. According to Dr. Greene, 'There are so many questions surrounding stem cell therapy from the public, and unfortunately there are many unscrupulous actors spreading misinformation. With R3's President Samantha Brechner as the host, we will provide accurate information to FAQ's in layman's terms so people understand what these wonderful therapies can or can't do!' With over 26,000 stem cell procedures performed in the past decade, R3 Stem Cell has over 70 Centers in 7 countries. The company has published 10 peer reviewed research papers over the past 2 years, on regenerative therapies for conditions such as autism, Cerebral Palsy, premature ovarian failure, diabetes and more. With an incredibly broad experience, R3's CEO Dr. David Greene is able to convey a deep understanding of not just what the biologics are, but how they work for individuals and what to expect. Dr. Greene added, 'I'm not interested in fluff content involving stem cell research that won't help people. The topics are directly tied to existing therapies that are changing lives every day. For example, stem cell therapy for autism works amazingly well and is safe. Parents need the latest information to be able to make educated decisions regarding their child's healthcare.' R3 Stem Cell has stem cell clinics in Turkey, Philippines, Pakistan, India, Mexico, USA and South Africa. Each clinic utilizes R3's biologics and best practice protocols. New episodes will be added weekly, with the Stem Cell Genius podcast being available on all major content platforms. David Greene, MD, PhD, MBA R3 Stem Cell International +1 (888) 988-0515 email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
The Independent
21-05-2025
- Health
- The Independent
DNA ‘barcodes' shed light on how the blood ages
Scientists have discovered 'barcodes' embedded in DNA that shed light on how the blood ages. It is hoped the discovery could help prevent illnesses such as blood cancer or heart disease before symptoms appear. It could also pave the way for the exploration of therapies that slow down or reverse ageing, researchers suggested. The study, published in the journal Nature, identified stem cells that gradually take over blood production between the ages of 50 and 60. These cells, known as 'clones', prefer to produce myeloid cells, a type of immune cell linked to chronic inflammation. Young people have between 50,000 and 200,000 stem cells, which are responsible for replacing between 100 billion and 200 billion blood cells every day. 'As we age, some of these stem cells disappear and their function needs to be taken over by others, which then expand,' said Dr Lars Velten, group leader at the Centre for Genomic Regulation (CRG) in Barcelona. 'And by the age of 50 or 60, we get these clones. This is a group of cells that stem from the same mother stem cell. 'And these clones are important because they are first step in leukaemia formation, and they also contribute to inflammation, because the blood cells that derive from them are emitting molecules that fuel the inflammation process, and therefore there's also this link to heart disease risk.' According to Dr Velten, tracking every blood cell back to its original stem cell has been possible only in animal research. His team looked at changes in the chemical tags, known as methylation marks, attached to DNA. Theses tags help cells know which genes to switch on and off, and when a stem cell divides, methylation marks are copied to its daughter cells. 'This is sort of like having a unique barcode for every cell when we're young, and then this barcode identifies all the descendants, all the children and grandchildren and great-grandchildren, of these cells as we age,' Dr Velten added. To read these 'barcodes', scientists developed a technique known as EPI-Clone. They used it to reconstruct the history of blood production in both mice and humans, tracing which stem cells contributed to making blood. In older mice, EPI-Clone showed that blood stem cells comprised just a few dozen large clones. The pattern was also found in humans, with larger clones taking over blood production from age 50. This discovery could one day allow doctors to look at how a patient's blood is ageing, potentially years before diseases develop, researchers suggested. Dr Alejo Rodriguez-Fraticelli, also group leader at IRB Barcelona, said: 'The idea is that this could be an early intervention tool for cancers, starting with blood cancers, where we know that expansions in these stem cells identify individuals that are at risk of developing blood malignancies.' The study also found many of the dominant clones produced myeloid cells, which are linked to chronic inflammation. Research using mice has shown removing these particular clones can rejuvenate blood stem cells. Researchers are hopeful the tool could pave the way for the exploration of rejuvenation therapies in humans as it allows for scientists to pinpoint problematic clones. Dr Rodriguez-Fraticelli added: 'If we target the expanded clones, there may be the hope that we may ablate them and then let the diversity of the hematopoietic system, the blood regeneration system, really rejuvenate.' Dr Velten said: 'If we want to move beyond generic anti-ageing treatments and into real precision medicine for ageing, this is exactly the kind of tool we need. 'We can't fix what we can't see and for the first time, EPI-Clone can facilitate this for humans.'
Japan Times
14-05-2025
- Health
- Japan Times
Finally, a source of hope for Parkinson's disease sufferers
Two small studies published just recently in Nature offer early, but important validation that stem cell treatments for Parkinson's disease are viable. They also are a step toward a future where stem cells can be used not just to treat, but ideally to repair or prevent damage to the brain. Getting there will take incredible coordination and a continued commitment to understanding the drivers of neurodegenerative diseases; we can't fix what we don't know is broken. The treatments, one originally developed by a team at Memorial Sloan Kettering Cancer Center in New York and the other by researchers in Kyoto, Japan, are the culmination of decades of work to figure out how to turn stem cells into functional therapies for Parkinson's. (To be clear, these stem cells are designed in a lab and are not the same as the dubious therapies sold in stem cell clinics — none of which are FDA-approved.) Parkinson's disease is marked by a loss of neurons that make dopamine, a chemical messenger involved in movement and coordination. By the time someone shows signs of the disease such as a hand tremor or muscle stiffness, they have already lost anywhere from 60 to 80% of those nerve cells in the part of the brain that controls movement. Since the 1990s, researchers have imagined using stem cells to replace those lost neurons. Finally, it seems, they are figuring out the right set of cues to prompt stem cells to turn into dopamine-producing nerve cells. Moreover, these two experiments, which together tested separate therapies across 18 patients, offered hints that those cells, once implanted in the brain, might work as intended. The main goal of both studies was to ensure the stem cells were safe, well tolerated and feasible as a therapeutic. So far, so good. There was one small caveat: Because the treatments were made with donor stem cells rather than the patient's own cells, (an "off the shelf' approach that could make them easier to commercialize), participants initially had to take immunosuppressants to keep their bodies from rejecting the therapy, and some experienced mild to moderate side effects related to those drugs. Even better, the cells settled right into their environment and seemed to be functional even after people stopped taking immunosuppressants. Once implanted, a relatively straightforward procedure where millions of cells are carefully distributed in a part of the brain, the young nerve cells need to mature and form the right connections to their neighbors before they can start shipping out dopamine. That process takes many months, but the hope is that once that network is in place, these cells could be functional for many years, perhaps even for the rest of a Parkinson's patient's life. Using an imaging technique that lights up the endings of the nerve cells that make dopamine, the researchers showed that people continued to produce more of the neurotransmitter than before the transplant. And both research groups also found promising, but preliminary signs that the approach could improve motor symptoms and potentially quality of life for some patients. Of course, much more work is needed to prove these treatments work. Researchers must affirm their safety in larger studies and better understand whether these cells remain functional for the long term and can make a meaningful difference in patients' lives. To that end, BlueRock Therapeutics, a subsidiary of Bayer that licensed Memorial Sloan Kettering's stem cell technology related to Parkinson's, has begun a Phase 3 trial to test its treatment in roughly 100 people. Multiple other, earlier studies are under way to test other stem cell approaches in Parkinson's. Eventually, Parkinson's patients will have to decide if they even want these therapies. In the years it has taken researchers to get to this promising stage, better ways of delivering dopamine precursors to the brain or treat the movement symptoms of Parkinson's using deep brain stimulation have emerged. Regardless, this is an important advance, perhaps even more so for the promise it holds for other brain diseases. Proving that stem cells can be safely implanted in the brain is a step toward researchers' ultimate dream of designing therapies that go beyond symptoms and can actually fix the brain or even protect it from future damage. "This is a proof of concept that we can repair parts of the brain, to give it new life and function, which opens the door to other neurological disorders,' says Viviane Tabar, a stem cell biologist and neurosurgeon at Memorial Sloan Kettering Cancer Center. Designing those therapies is by now the easy part, says Lorenz Studer, director of MSK's Center for Stem Cell Biology. "Things are going to go much more quickly, from an engineering perspective.' But, Studer cautions, understanding the right way to apply those tools — in other words, knowing what support cell or nerve cell to deliver into the brain — continues to be a challenge. There's a huge amount of work ahead, but this proof of concept in Parkinson's should be motivation to keep pushing — both at the basic biology and at driving stem cell treatments forward. Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry.
Health Line
12-05-2025
- Health
- Health Line
Understanding the Potential of Stem Cell Therapy for Diabetes Type 2
Stem cell therapy is an emerging treatment for type 2 diabetes. Although it's not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research. Stem cells are special human cells that can become many different types of cells. Because of this special property, doctors are investigating the potential of stem cell therapy to treat many conditions. People with type 2 diabetes don't make an adequate amount of insulin to manage their blood sugar. Stem cell therapy may potentially allow people with type 2 diabetes to start producing more insulin again and reduce the need for medications. The effectiveness and safety of stem cell therapy for treating diabetes are still under investigation, but some early studies have found promising results. What is stem cell therapy? Stem cell therapy involves taking stem cells from your body or another human's to help regenerate damaged tissues. Stem cells can be collected from fetal and adult tissues, such as: fat tissue umbilical cord bone marrow placenta How is stem cell therapy being used to treat type 2 diabetes? The diabetes epidemic remains one of the biggest health crises in the United States. Roughly 1 in 10 people in the United States has diabetes, with the majority having type 2. Researchers continue looking for new treatment options, and stem cell therapy has emerged as a promising option. Its use in humans is still being investigated, and more research is needed to assess its long-term effectiveness and safety accurately. According to the authors of a 2025 letter to the editor, their team identified 143 diabetes stem cell therapy clinical trials worldwide from 2000 to 2024. Of these, 19 trials were ongoing. Research on type 2 diabetes Most research to date has examined stem cell therapy as a treatment for type 1 diabetes. In 2008, a team of researchers recruited a small group of 25 people with type 2 diabetes for a phase 1 clinical trial examining the effectiveness of stem cell therapy combined with hyperbaric oxygen treatment. The researchers found that all measured markers, such as fasting glucose levels and insulin requirement, improved at a one-year follow-up. Since then, more studies have continued to find evidence that stem cell therapy may potentially improve blood sugar management and reduce the need for diabetes medications. Further ongoing trials have also shown that stem cell therapy may help improve diabetic complications such as: diabetic foot ulcers erectile dysfunction diabetic peripheral neuropathy Modern research In 2024, researchers reported a groundbreaking case of a 25-year-old woman with type 1 diabetes who started producing insulin within three months of receiving a stem cell transplant, effectively reversing her diabetes. The results of current trials for type 2 diabetes look promising. Future research will focus on analyzing long-term results and safety in larger groups. Many clinical trials are currently underway. For instance, one clinical trial that's currently recruiting is examining the effectiveness of stem cell therapy for treating type 2 diabetes that hasn't responded to other treatments. A phase II clinical trial that isn't yet in the recruiting phase is examining the effectiveness and safety of a type of stem cell therapy that involves taking cells from your own body. How does stem cell therapy compare to traditional treatments for type 2 diabetes? Treatment for type 2 diabetes typically consists of making lifestyle changes and sometimes taking medications. Commonly prescribed medications include: metformin sulfonylureas glinides GLP-1 receptor agonists DPP-4 inhibitors Thiazolidnediones These medications help improve your blood sugar management, but they need to be taken continuously to be effective. Stem cell therapy is an attractive alternative since it can potentially be curative after one treatment. Who is a good candidate for stem cell therapy for type 2 diabetes? Stem cell therapy is still an experimental treatment. Researchers are continuing to see who might make a good candidate. For now, researchers may offer it as an experimental treatment for people who haven't responded to other treatments. What are the risks of having stem cell therapy for type 2 diabetes? Researchers are continuing to examine the safety of stem cell therapy for type 2 diabetes. Some concern is that it could encourage tumor formation. Side effects reported in clinical trials included: fever bruising nausea vomiting headache hypoglycemia What is the success rate for stem cell therapy as a treatment for type 2 diabetes? Improvements in blood sugar management have been reported in as little as weeks. For example, in a 2024 case study, researchers observed improvements in a 59-year-old man with severe diabetes complications within 2 weeks. Studies consistently show improvements in blood sugar management, but larger studies are needed to understand the actual success rate. Where can you have stem cell therapy for type 2 diabetes? Stem cell therapy for type 2 diabetes is still under investigation. In the United States, thousands of clinics have appeared offering unlicensed and unproven stem cell therapies. The FDA hasn't yet approved stem cell therapies for diabetes. What does cell therapy for type 2 diabetes cost? Stem cell therapy isn't yet available for treating type II diabetes in the United States. Because it's not approved for use, it's also not covered by insurance. To get a rough idea of the cost, in one study, researchers estimated that the average price of stem cell therapy for diabetes might range from $5,000 to $50,000. What's the outlook for people who have stem cell therapy for type 2 diabetes? Little research examines the long-term effectiveness of stem cell therapy for diabetes. Most current studies have had follow-ups shorter than 1–2 years. Although it shows a lot of promise, more research is needed to judge long-term results accurately. Can you still have traditional treatment during or after stem cell therapy? Some people seem to reduce their need for medications or can stop taking medications altogether after stem cell therapy. Takeaway Stem cell therapy is being investigated as a potential treatment for type 2 diabetes. In theory, it may allow the body to produce more insulin to better regulate blood sugar levels. Stem cell therapy isn't yet FDA-approved in the United States for treating diabetes, but researchers continue examining its safety and effectiveness. The field of stem cell therapy is expanding rapidly, so it's likely that many more studies will be completed in the next few years.
